Anna L Fracanzani

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/439333/publications.pdf

Version: 2024-02-01

206 papers	15,139 citations	16411 64 h-index	20307 116 g-index
210 all docs	210 docs citations	210 times ranked	16876 citing authors

#	Article	IF	Citations
1	Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?. Gut, 2022, 71, 382-390.	6.1	113
2	Factors affecting longâ€term changes of liver stiffness in directâ€acting antiâ€hepatitis C virus therapy: A multicentre prospective study. Journal of Viral Hepatitis, 2022, 29, 26-34.	1.0	10
3	MAFLD definition underestimates the risk to develop HCC in genetically predisposed patients. Journal of Internal Medicine, 2022, 291, 374-376.	2.7	8
4	Low Lipoprotein(a) Levels Predict Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Hepatology Communications, 2022, 6, 535-549.	2.0	18
5	TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in InÂVitro Models. Cellular and Molecular Gastroenterology and Hepatology, 2022, 13, 759-788.	2.3	44
6	Hypercoagulability in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD): Causes and Consequences. Biomedicines, 2022, 10, 249.	1.4	16
7	PSD3 downregulation confers protection against fatty liver disease. Nature Metabolism, 2022, 4, 60-75.	5.1	15
8	A prospective study of directâ€acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort. Hepatology, 2022, 76, 220-232.	3.6	12
9	Impact of Sarcopenia and Myosteatosis in Non-Cirrhotic Stages of Liver Diseases: Similarities and Differences across Aetiologies and Possible Therapeutic Strategies. Biomedicines, 2022, 10, 182.	1.4	15
10	Interaction between Lifestyle Changes and PNPLA3 Genotype in NAFLD Patients during the COVID-19 Lockdown. Nutrients, 2022, 14, 556.	1.7	10
11	PD-1/PD-L1 Immuno-Mediated Therapy in NAFLD: Advantages and Obstacles in the Treatment of Advanced Disease. International Journal of Molecular Sciences, 2022, 23, 2707.	1.8	9
12	A cholestatic pattern predicts major liverâ€related outcomes in patients with nonâ€alcoholic fatty liver disease. Liver International, 2022, 42, 1037-1048.	1.9	4
13	Rare ATG7 genetic variants predispose patients to severe fatty liver disease. Journal of Hepatology, 2022, 77, 596-606.	1.8	38
14	Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by direct-acting antiviral therapy (DAAs): Evaluation by the controlled attenuation parameter (CAP). Digestive and Liver Disease, 2021, 53, 1301-1307.	0.4	6
15	Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease. Clinical Gastroenterology and Hepatology, 2021, 19, 806-815.e5.	2.4	90
16	The multifaceted spectrum of liver cirrhosis in older hospitalised patients: analysis of the REPOSI registry. Age and Ageing, 2021, 50, 498-504.	0.7	1
17	Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. Journal of Hepatology, 2021, 74, 775-782.	1.8	193
18	Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study. Journal of Allergy and Clinical Immunology, 2021, 147, 561-566.e4.	1.5	90

#	Article	IF	Citations
19	PCSK9 rs11591147 R46L lossâ€ofâ€function variant protects against liver damage in individuals with NAFLD. Liver International, 2021, 41, 321-332.	1.9	26
20	The KLB rs17618244 gene variant is associated with fibrosing MAFLD by promoting hepatic stellate cell activation. EBioMedicine, 2021, 65, 103249.	2.7	11
21	The rs599839 A>G Variant Disentangles Cardiovascular Risk and Hepatocellular Carcinoma in NAFLD Patients. Cancers, 2021, 13, 1783.	1.7	16
22	Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort. Digestive and Liver Disease, 2021, 53, 1603-1609.	0.4	2
23	Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 2345-2353.	1.1	40
24	NR1H4 rs35724 G>C variant modulates liver damage in nonalcoholic fatty liver disease. Liver International, 2021, 41, 2712-2719.	1.9	6
25	Impact of implementing a Choosing Wisely educational intervention into clinical practice: The CW-SIMI study (a multicenter-controlled study). European Journal of Internal Medicine, 2021, 93, 71-77.	1.0	4
26	Congenital Hepatic Fibrosis as a Cause of Recurrent Cholangitis: A Case Report and Review of the Literature. Livers, 2021, 1, 132-137.	0.8	2
27	Ceruloplasmin gene variants are associated with hyperferritinemia and increased liver iron in patients with NAFLD. Journal of Hepatology, 2021, 75, 506-513.	1.8	40
28	Î±-Lipoic Acid Improves Hepatic Metabolic Dysfunctions in Acute Intermittent Porphyria: A Proof-of-Concept Study. Diagnostics, 2021, 11, 1628.	1.3	5
29	Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis. Lancet Rheumatology, The, 2021, 3, e690-e697.	2.2	121
30	Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease. Journal of Hepatology, 2021, 75, 786-794.	1.8	100
31	Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial. Nature Medicine, 2021, 27, 1825-1835.	15.2	98
32	Genetics, Immunity and Nutrition Boost the Switching from NASH to HCC. Biomedicines, 2021, 9, 1524.	1.4	10
33	Variants in PCSK7, PNPLA3 and TM6SF2 are risk factors for the development of cirrhosis in hereditary haemochromatosis. Alimentary Pharmacology and Therapeutics, 2021, 53, 830-843.	1.9	9
34	FibroScan Identifies Patients With Nonalcoholic Fatty Liver Disease and Cardiovascular Damage. Clinical Gastroenterology and Hepatology, 2020, 18, 517-519.	2.4	12
35	High prevalence of early atherosclerotic and cardiac damage in patients undergoing liver transplantation: Preliminary results. Digestive and Liver Disease, 2020, 52, 84-90.	0.4	3
36	Î²-Klotho gene variation is associated with liver damage in children with NAFLD. Journal of Hepatology, 2020, 72, 411-419.	1.8	48

#	Article	IF	Citations
37	Impact of natural neuromedinâ€Β receptor variants on iron metabolism. American Journal of Hematology, 2020, 95, 167-177.	2.0	7
38	Liver fibrosis by FibroScan^{Â®} independently of established cardiovascular risk parameters associates with macrovascular and microvascular complications in patients with type 2 diabetes. Liver International, 2020, 40, 347-354.	1.9	59
39	Long-term evaluation of liver stiffness in HCV patients after sustained virological response to DAAs: predictive factors for disease improvement and hepatocellular carcinoma development. Journal of Hepatology, 2020, 73, S623-S624.	1.8	0
40	Neurotensin up-regulation is associated with advanced fibrosis and hepatocellular carcinoma in patients with MAFLD. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2020, 1865, 158765.	1.2	10
41	NAFLD fibrosis score (NFS) can be used in outpatient services to identify chronic vascular complications besides advanced liver fibrosis in type 2 diabetes. Journal of Diabetes and Its Complications, 2020, 34, 107684.	1.2	11
42	Nutrients, Genetic Factors, and Their Interaction in Non-Alcoholic Fatty Liver Disease and Cardiovascular Disease. International Journal of Molecular Sciences, 2020, 21, 8761.	1.8	27
43	Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by directâ€acting antiviral therapy: A prospective study. Diabetes, Obesity and Metabolism, 2020, 22, 2408-2416.	2.2	58
44	MBOAT7 down-regulation by genetic and environmental factors predisposes to MAFLD. EBioMedicine, 2020, 57, 102866.	2.7	38
45	MAFLD in COVID-19 patients: an insidious enemy. Expert Review of Gastroenterology and Hepatology, 2020, 14, 867-872.	1.4	23
46	Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease. American Journal of Gastroenterology, 2020, 115, 1289-1292.	0.2	9
47	A polygenic risk score for progressive non-alcoholic fatty liver disease risk stratification. Journal of Hepatology, 2020, 73, S13-S14.	1.8	4
48	Genetic variants in the MTHFR are not associated with fatty liver disease. Liver International, 2020, 40, 1934-1940.	1.9	5
49	Genomewide Association Study of Severe Covid-19 with Respiratory Failure. New England Journal of Medicine, 2020, 383, 1522-1534.	13.9	1,548
50	Reply to Comment: Is there any place for SGLT2-inhibitors in post-liver transplantation patients?. Digestive and Liver Disease, 2020, 52, 470-471.	0.4	0
51	Mboat7 down-regulation by hyper-insulinemia induces fat accumulation in hepatocytes. EBioMedicine, 2020, 52, 102658.	2.7	71
52	Liver involvement in Gaucher disease: A practical review for the hepatologist and the gastroenterologist. Digestive and Liver Disease, 2020, 52, 368-373.	0.4	15
53	Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis. Journal of Hepatology, 2020, 73, 593-602.	1.8	38
54	Liver transcriptomics highlights interleukin-32 as novel NAFLD-related cytokine and candidate biomarker. Gut, 2020, 69, 1855-1866.	6.1	75

#	Article	IF	Citations
55	Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study. Atherosclerosis, 2020, 296, 40-47.	0.4	78
56	Combined use of Genetic Polymorphisms and Elastographic Techniques in NAFLD: Fact or Fiction?. Current Pharmaceutical Design, 2020, 26, 1010-1018.	0.9	4
57	Dysmetabolic Hyperferritinemia and Dysmetabolic Iron Overload Syndrome (DIOS): Two Related Conditions or Different Entities?. Current Pharmaceutical Design, 2020, 26, 1025-1035.	0.9	26
58	Prevalence of use and appropriateness of antidepressants prescription in acutely hospitalized elderly patients. European Journal of Internal Medicine, 2019, 68, e7-e11.	1.0	2
59	Procoagulant imbalance influences cardiovascular and liver damage in chronic hepatitis C independently of steatosis. Liver International, 2019, 39, 2309-2316.	1.9	8
60	mir-101-3p Downregulation Promotes Fibrogenesis by Facilitating Hepatic Stellate Cell Transdifferentiation During Insulin Resistance. Nutrients, 2019, 11, 2597.	1.7	24
61	Lipid accumulation impairs lysosomal acid lipase activity in hepatocytes: Evidence in NAFLD patients and cell cultures. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2019, 1864, 158523.	1.2	17
62	Evaluation of three â€œbeyond Baveno VIâ€•criteria to safely spare endoscopies in compensated advanced chronic liver disease. Digestive and Liver Disease, 2019, 51, 1135-1140.	0.4	18
63	Serum coding and nonâ€coding RNAs as biomarkers of NAFLD and fibrosis severity. Liver International, 2019, 39, 1742-1754.	1.9	51
64	Brain involvement in non-alcoholic fatty liver disease (NAFLD): A systematic review. Digestive and Liver Disease, 2019, 51, 1214-1222.	0.4	52
65	PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients. Journal of Lipid Research, 2019, 60, 1144-1153.	2.0	42
66	Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. Scientific Reports, 2019, 9, 3682.	1.6	85
67	Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis. Clinical Gastroenterology and Hepatology, 2019, 17, 2310-2319.e6.	2.4	66
68	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet, The, 2019, 394, 2184-2196.	6.3	818
69	Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver Disease. American Journal of Gastroenterology, 2019, 114, 916-928.	0.2	57
70	Progressive splenomegaly and mild thrombocytosis in beta-thalassaemia trait and coexisting hereditary hemochromatosis: possible confounders for a subsequent hematological diagnosis. Internal and Emergency Medicine, 2019, 14, 763-766.	1.0	0
71	A sweet fever. Internal and Emergency Medicine, 2019, 14, 1125-1128.	1.0	0
72	Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis. Journal of Hepatology, 2018, 69, 18-24.	1.8	98

#	Article	IF	Citations
73	Harmful and Beneficial Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis. Clinical Gastroenterology and Hepatology, 2018, 16, 1146-1152.e4.	2.4	77
74	miRNA Signature in NAFLD: A Turning Point for a Non-Invasive Diagnosis. International Journal of Molecular Sciences, 2018, 19, 3966.	1.8	98
75	Protein phosphatase 1 regulatory subunit 3B gene variation protects against hepatic fat accumulation and fibrosis in individuals at high risk of nonalcoholic fatty liver disease. Hepatology Communications, 2018, 2, 666-675.	2.0	38
76	Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis. Journal of Hepatology, 2018, 69, 878-885.	1.8	113
77	Subclinical cerebrovascular disease in NAFLD without overt risk factors for atherosclerosis. Atherosclerosis, 2018, 268, 27-31.	0.4	19
78	Fibronectin Type III Domainâ€“Containing Protein 5 rs3480 A>G Polymorphism, Irisin, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2660-2669.	1.8	42
79	Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity. Clinical Gastroenterology and Hepatology, 2017, 15, 1604-1611.e1.	2.4	146
80	Severe reduction of blood lysosomal acid lipase activity in cryptogenic cirrhosis: A nationwide multicentre cohort study. Atherosclerosis, 2017, 262, 179-184.	0.4	19
81	Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. Cancer Medicine, 2017, 6, 1930-1940.	1.3	43
82	Interferon lambda 4 rs368234815 TT>ÎŤG variant is associated with liver damage in patients with nonalcoholic fatty liver disease. Hepatology, 2017, 66, 1885-1893.	3.6	75
83	PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans. European Journal of Preventive Cardiology, 2017, 24, 1870-1877.	0.8	55
84	MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals. Scientific Reports, 2017, 7, 4492.	1.6	193
85	Procoagulant imbalance in patients with non-alcoholic fatty liver disease. Journal of Hepatology, 2017, 66, 248-250.	1.8	123
86	Vascular Damage in Patients with Nonalcoholic Fatty Liver Disease: Possible Role of Iron and Ferritin. International Journal of Molecular Sciences, 2016, 17, 675.	1.8	12
87	Epicardial Adipose Tissue (EAT) Thickness Is Associated with Cardiovascular and Liver Damage in Nonalcoholic Fatty Liver Disease. PLoS ONE, 2016, 11, e0162473.	1.1	41
88	Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease. PLoS ONE, 2016, 11, e0163069.	1.1	63
89	The rs2294918 E434K variant modulates patatinâ€like phospholipase domainâ€containing 3 expression and liver damage. Hepatology, 2016, 63, 787-798.	3.6	93
90	Liver fat accumulation is associated with circulating PCSK9. Annals of Medicine, 2016, 48, 384-391.	1.5	119

#	Article	IF	Citations
91	Progression of carotid vascular damage and cardiovascular events in non-alcoholic fatty liver disease patients compared to the general population during 10Âyears of follow-up. Atherosclerosis, 2016, 246, 208-213.	0.4	78
92	Cardiovascular risk after orthotopic liver transplantation, a review of the literature and preliminary results of a prospective study. World Journal of Gastroenterology, 2016, 22, 8869.	1.4	22
93	High Fat Diet Subverts Hepatocellular Iron Uptake Determining Dysmetabolic Iron Overload. PLoS ONE, 2015, 10, e0116855.	1.1	47
94	Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology, 2015, 61, 506-514.	3.6	424
95	The <scp>UCP</scp>2 â€866ÂG>A promoter region polymorphism is associated with nonalcoholic steatohepatitis.. Liver International, 2015, 35, 1574-1580.	1.9	41
96	Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients. Hepatology, 2015, 62, 111-117.	3.6	52
97	Increased circulating adiponectin in males with chronic HCV hepatitis. European Journal of Internal Medicine, 2015, 26, 635-639.	1.0	6
98	Ovarian senescence increases liver fibrosis in humans and zebrafish with steatosis. DMM Disease Models and Mechanisms, 2015, 8, 1037-46.	1.2	52
99	Nonalcoholic fatty liver disease and vascular disease: State-of-the-art. World Journal of Gastroenterology, 2014, 20, 13306.	1.4	171
100	Juvenile hemochromatosis associated with heterozygosity for novel hemojuvelin mutations and with unknown cofactors. Annals of Hepatology, 2014, 13, 568-571.	0.6	5
101	Hepatic steatosis and <scp>PNPLA</scp>3 I148<scp>M</scp> variant are associated with serum <scp>F</scp>etuinâ€<scp>A</scp> independently of insulin resistance. European Journal of Clinical Investigation, 2014, 44, 627-633.	1.7	24
102	Role of iron in hepatocellular carcinoma. Clinical Liver Disease, 2014, 3, 108-110.	1.0	23
103	Procoagulant imbalance in patients with non-alcoholic fatty liver disease. Journal of Hepatology, 2014, 61, 148-154.	1.8	149
104	Risk of Obstructive Sleep Apnea with Daytime Sleepiness Is Associated with Liver Damage in Non-Morbidly Obese Patients with Nonalcoholic Fatty Liver Disease. PLoS ONE, 2014, 9, e96349.	1.1	31
105	A randomized trial of iron depletion in patients with nonalcoholic fatty liver disease and hyperferritinemia. World Journal of Gastroenterology, 2014, 20, 3002.	1.4	85
106	Juvenile hemochromatosis associated with heterozygosity for novel hemojuvelin mutations and with unknown cofactors. Annals of Hepatology, 2014, 13, 568-71.	0.6	1
107	Liver transplantation for hepatocellular carcinoma in a patient with a novel telomerase mutation and steatosis. Journal of Hepatology, 2013, 58, 399-401.	1.8	14
108	Stage of change and motivation to healthier lifestyle in non-alcoholic fatty liver disease. Journal of Hepatology, 2013, 58, 771-777.	1.8	74

#	Article	IF	Citations
109	Mortality Risk According to Different Clinical Characteristics of First Episode of Liver Decompensation in Cirrhotic Patients: A Nationwide, Prospective, 3-Year Follow-Up Study in Italy. American Journal of Gastroenterology, 2013, 108, 1112-1122.	0.2	43
110	PNPLA3 GG Genotype and Carotid Atherosclerosis in Patients with Non-Alcoholic Fatty Liver Disease. PLoS ONE, 2013, 8, e74089.	1.1	59
111	PNPLA3 I148M Polymorphism, Clinical Presentation, and Survival in Patients with Hepatocellular Carcinoma. PLoS ONE, 2013, 8, e75982.	1.1	42
112	Effect of the A736V TMPRSS6 polymorphism on the penetrance and clinical expression of hereditary hemochromatosis. Journal of Hepatology, 2012, 57, 1319-1325.	1.8	33
113	The SOD2 C47T polymorphism influences NAFLD fibrosis severity: Evidence from case-control and intra-familial allele association studies. Journal of Hepatology, 2012, 56, 448-454.	1.8	156
114	The i148m Pnpla3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls. BMC Gastroenterology, 2012, 12, 111.	0.8	62
115	The A736V TMPRSS6 Polymorphism Influences Hepatic Iron Overload in Nonalcoholic Fatty Liver Disease. PLoS ONE, 2012, 7, e48804.	1.1	42
116	Gallstone Disease Is Associated with More Severe Liver Damage in Patients with Non-Alcoholic Fatty Liver Disease. PLoS ONE, 2012, 7, e41183.	1.1	51
117	CYBRD1 as a modifier gene that modulates iron phenotype in HFE p.C282Y homozygous patients. Haematologica, 2012, 97, 1818-1825.	1.7	34
118	Patatin-like phospholipase domain containing-3gene I148M polymorphism, steatosis, and liver damage in hereditary hemochromatosis. World Journal of Gastroenterology, 2012, 18, 2813.	1.4	50
119	Beyond hereditary hemochromatosis: New insights into the relationship between iron overload and chronic liver diseases. Digestive and Liver Disease, 2011, 43, 89-95.	0.4	69
120	Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity. Journal of Hepatology, 2011, 54, 1244-1249.	1.8	107
121	The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver. Journal of Hepatology, 2011, 55, 1409-1414.	1.8	74
122	Iron in fatty liver and in the metabolic syndrome: A promising therapeutic target. Journal of Hepatology, 2011, 55, 920-932.	1.8	279
123	Serum ferritin levels are associated with vascular damage in patients with nonalcoholic fatty liver disease. Nutrition, Metabolism and Cardiovascular Diseases, 2011, 21, 568-575.	1.1	78
124	A tetra-primer amplification refractory mutation system polymerase chain reaction for the evaluation of rs12979860 IL28B genotype. Journal of Viral Hepatitis, 2011, 18, 628-630.	1.0	24
125	Patatin-Like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology, 2011, 53, 791-799.	3.6	227
126	Serum Hepcidin and Macrophage Iron Correlate With MCP-1 Release and Vascular Damage in Patients With Metabolic Syndrome Alterations. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 683-690.	1.1	78

#	Article	IF	Citations
127	Venesection for non-alcoholic fatty liver disease unresponsive to lifestyle counselling--a propensity score-adjusted observational study. QJM - Monthly Journal of the Association of Physicians, 2011, 104, 141-149.	0.2	64
128	Hemochromatosis in Italy in the last 30 years: Role of genetic and acquired factors. Hepatology, 2010, 51, 501-510.	3.6	35
129	Hemochromatosis gene (HFE) mutations and cancer risk: Expanding the clinical manifestations of hereditary iron overload. Hepatology, 2010, 51, 1119-1121.	3.6	41
130	Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology, 2010, 51, 1209-1217.	3.6	563
131	Lack of association between peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms and progressive liver damage in patients with non-alcoholic fatty liver disease: a case control study. BMC Gastroenterology, 2010, 10, 102.	0.8	53
132	Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. Gut, 2010, 59, 267-273.	6.1	148
133	A Promoter Polymorphism in the Liver-specific Fatty Acid Transport Protein 5 is Associated with Features of the Metabolic Syndrome and Steatosis. Hormone and Metabolic Research, 2010, 42, 854-859.	0.7	38
134	HFE Genotype, Parenchymal Iron Accumulation, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology, 2010, 138, 905-912.	0.6	246
135	Beta-globin mutations are associated with parenchymal siderosis and fibrosis in patients with non-alcoholic fatty liver disease. Journal of Hepatology, 2010, 53, 927-933.	1.8	60
136	Iron-Dependent Regulation of MDM2 Influences p53 Activity and Hepatic Carcinogenesis. American Journal of Pathology, 2010, 176, 1006-1017.	1.9	68
137	Reply:. Hepatology, 2009, 49, 697-697.	3.6	3
138	Can nonalcoholic steatohepatitis trigger porphyria cutanea tarda clinical manifestations?. Internal and Emergency Medicine, 2009, 4, 91-92.	1.0	3
139	Association between iron overload and osteoporosis in patients with hereditary hemochromatosis. Osteoporosis International, 2009, 20, 549-555.	1.3	158
140	The immunopathogenesis of alcoholic and nonalcoholic steatohepatitis: two triggers for one disease?. Seminars in Immunopathology, 2009, 31, 359-369.	2.8	89
141	Ferroportin-1 in the recurrence of hepatic iron overload after liver transplantation. Digestive and Liver Disease, 2009, 41, e17-e20.	0.4	3
142	Serum Ferritin Levels Are Associated with Vascular Damage in Patients with Nonalcoholic Fatty Liver Disease.. Blood, 2009, 114, 5098-5098.	0.6	0
143	HFEmutations in nonalcoholic fatty liver disease. Hepatology, 2008, 47, 1794-1795.	3.6	11
144	Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes. Hepatology, 2008, 48, 792-798.	3.6	600

#	Article	IF	Citations
145	Risk of severe liver disease in nonalcoholic fatty liver disease: Role of insulin resistance. Hepatology, 2008, 48, 2088-2088.	3.6	3
146	Iron genes, dysmetabolism and fibrosis in chronic hepatitis C. Journal of Hepatology, 2008, 48, 513-514.	1.8	3
147	Carotid Artery Intima-media Thickness in Nonalcoholic Fatty Liver Disease. American Journal of Medicine, 2008, 121, 72-78.	0.6	189
148	Iron Depletion by Deferoxamine Up-Regulates Glucose Uptake and Insulin Signaling in Hepatoma Cells and in Rat Liver. American Journal of Pathology, 2008, 172, 738-747.	1.9	144
149	Bloodletting Ameliorates Insulin Sensitivity and Secretion in Parallel to Reducing Liver Iron in Carriers of HFE Gene Mutations: Response to Equitani et al.. Diabetes Care, 2008, 31, e18-e18.	4.3	8
150	Increased Expression and Activity of the Transcription Factor FOXO1 in Nonalcoholic Steatohepatitis. Diabetes, 2008, 57, 1355-1362.	0.3	163
151	<i>HFE</i> Genotype Influences Erythropoiesis Support Requirement in Hemodialysis Patients: A Prospective Study. American Journal of Nephrology, 2008, 28, 311-316.	1.4	13
152	The hand arthropathy of hereditary hemochromatosis is strongly associated with iron overload. Journal of Rheumatology, 2008, 35, 153-8.	1.0	42
153	Relative contribution of iron genes, dysmetabolism and hepatitis C virus (HCV) in the pathogenesis of altered iron regulation in HCV chronic hepatitis. Haematologica, 2007, 92, 1037-1042.	1.7	66
154	Iron Depletion by Phlebotomy Improves Insulin Resistance in Patients With Nonalcoholic Fatty Liver Disease and Hyperferritinemia: Evidence from a Case-Control Study. American Journal of Gastroenterology, 2007, 102, 1251-1258.	0.2	274
155	HFE Gene Mutations and Oxidative Stress Influence Serum Ferritin, Associated with Vascular Damage, in Hemodialysis Patients. American Journal of Nephrology, 2007, 27, 101-107.	1.4	19
156	Î±1-Antitrypsin mutations in NAFLD: High prevalence and association with altered iron metabolism but not with liver damage. Hepatology, 2006, 44, 857-864.	3.6	88
157	TNFÎ± genotype affects TNFÎ± release, insulin sensitivity and the severity of liver disease in HCV chronic hepatitis. Journal of Hepatology, 2005, 43, 944-950.	1.8	35
158	Association between heterozygosity for HFE gene mutations and hepatitis viruses in hepatocellular carcinoma. Blood Cells, Molecules, and Diseases, 2005, 35, 27-32.	0.6	24
159	TNFÎ± Promoter Polymorphisms. , 2004, 98, 047-058.		14
160	Treatment choices for people infected with HCV. Journal of Antimicrobial Chemotherapy, 2004, 53, 708-712.	1.3	13
161	The mitochondrial superoxide dismutase A16V polymorphism in the cardiomyopathy associated with hereditary haemochromatosis. Journal of Medical Genetics, 2004, 41, 946-950.	1.5	81
162	CYTOTOXIC T-LYMPHOCYTE ANTIGEN-4 A49G POLYMORPHISM IS ASSOCIATED WITH SUSCEPTIBILITY TO AND SEVERITY OF ALCOHOLIC LIVER DISEASE IN ITALIAN PATIENTS. Alcohol and Alcoholism, 2004, 39, 276-280.	0.9	27

#	Article	IF	Citations
163	Searching for coeliac disease in patients with non-alcoholic fatty liver disease. Digestive and Liver Disease, 2004, 36, 333-336.	0.4	76
164	Coeliac disease and non-alcoholic fatty liver disease. Digestive and Liver Disease, 2004, 36, 781.	0.4	1
165	Non-alcoholic fatty liver disease: a multicentre clinical study by the Italian Association for the Study of the Liver. Digestive and Liver Disease, 2004, 36, 398-405.	0.4	56
166	Increased susceptibility to nonalcoholic fatty liver disease in heterozygotes for the mutation responsible for hereditary hemochromatosis. Digestive and Liver Disease, 2003, 35, 172-178.	0.4	84
167	Correspondence. Digestive and Liver Disease, 2003, 35, 596-597.	0.4	1
168	Effect of iron depletion in patients with nonalcoholic fatty liver disease without carbohydrate intolerance. Gastroenterology, 2003, 124, 866.	0.6	38
169	Sustained response to combination therapy in patients with chronic hepatitis C who failed to respond to interferon. Journal of Hepatology, 2003, 38, 499-505.	1.8	14
170	What is the contribution of differences in three measures of tumor necrosis factor-alpha activity to insulin resistance in healthy volunteers?. Metabolism: Clinical and Experimental, 2003, 52, 1593-1596.	1.5	10
171	Impact of large regenerative, low grade and high grade dysplastic nodules in hepatocellular carcinoma development. Journal of Hepatology, 2003, 39, 208-214.	1.8	182
172	Prevalence of hepatitis C virus infection in porphyria cutanea tarda. Journal of Hepatology, 2003, 39, 635-638.	1.8	25
173	Iron reduction and sustained response to interferon-Î± therapy in patients with chronic hepatitis C: results of an Italian multicenter randomized study. American Journal of Gastroenterology, 2002, 97, 1204-1210.	0.2	0
174	Tumor necrosis factor Î± promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology, 2002, 122, 274-280.	0.6	285
175	Iron reduction and sustained response to interferon-alpha therapy in patients with chronic hepatitis C: results of an Italian multicenter randomized study. American Journal of Gastroenterology, 2002, 97, 1204-1210.	0.2	77
176	Liver nodule and US medium contrast agents: Past and future. Hepatology, 2002, 36, 508-509.	3.6	1
177	Liver cancer risk is increased in patients with porphyria cutanea tarda in comparison to matched control patients with chronic liver disease. Journal of Hepatology, 2001, 35, 498-503.	1.8	73
178	Mutations in the HFE Gene and Their Interaction with Exogenous Risk Factors in Hepatocellular Carcinoma. Blood Cells, Molecules, and Diseases, 2001, 27, 505-511.	0.6	37
179	Tumor necrosis factor Î± promoter polymorphisms influence the phenotypic expression of hereditary hemochromatosis. Blood, 2001, 97, 3707-3712.	0.6	88
180	Autoantibodies to human cytosol: a marker of sporadic porphyria cutanea tarda. Clinical and Experimental Immunology, 2001, 126, 47-53.	1.1	6

#	Article	IF	Citations
181	Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with nonâ€“iron-related chronic liver disease. Hepatology, 2001, 33, 647-651.	3.6	208
182	Contrast-enhanced doppler ultrasonography in the diagnosis of hepatocellular carcinoma and premalignant lesions in patients with cirrhosis. Hepatology, 2001, 34, 1109-1112.	3.6	79
183	Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis. American Journal of Gastroenterology, 2001, 96, 2448-2455.	0.2	207
184	Molecular analysis of the TFR2 gene: Report of a novel polymorphism (1878C>T). Human Mutation, 2000, 16, 532-532.	1.1	4
185	Relationship between TNF-Î± and iron metabolism in differentiating human monocytic THP-1 cells. British Journal of Haematology, 2000, 110, 978-984.	1.2	52
186	Hereditary hemochromatosis in a patient with congenital dyserythropoietic anemia. Blood, 2000, 96, 3653-3655.	0.6	12
187	Iron and Liver Diseases. Canadian Journal of Gastroenterology & Hepatology, 2000, 14, 89D-92D.	1.8	13
188	Can Large Cell Change and High Proliferative Activity Predict Hepatocellular Carcinoma in Patients With Hereditary Hemochromatosis?. American Journal of Gastroenterology, 2000, 95, 2940-2945.	0.2	6
189	High prevalence of the His63Asp HFE mutation in italian patients with porphyria cutanea tarda. Hepatology, 1998, 27, 181-184.	3.6	195
190	Liver iron influences the response to interferon alpha therapy in chronic hepatitis C. European Journal of Gastroenterology and Hepatology, 1997, 9, 497-503.	0.8	69
191	No association between genetic hemochromatosis and alpha1-antitrypsin deficienc. Hepatology, 1996, 24, 1161-1164.	3.6	0
192	Genetic hemochromatosis in Italian patients with prophyria cutanea tarda: possible explanation for iron overload. Journal of Hepatology, 1996, 24, 564-569.	1.8	47
193	Portal hypertension and iron depletion in patients with genetic hemochromatosis. Hepatology, 1995, 22, 1127-1131.	3.6	42
194	Portal hypertension and iron depletion in patients with genetic hemochromatosis*1, *2. Hepatology, 1995, 22, 1127-1131.	3.6	1
195	Prognostic factors for hepatocellular carcinoma in genetic hemochromatosis. Hepatology, 1994, 20, 1426-1431.	3.6	116
196	Comparable frequency of hepatocellular carcinoma in cirrhosis of different aetiology. European Journal of Gastroenterology and Hepatology, 1994, 6, 1129-1134.	0.8	11
197	Liver damage in Italian patients with hereditary hemochromatosis is highly influenced by hepatitis B and C virus infection. Journal of Hepatology, 1992, 16, 364-368.	1.8	74
198	Functional roles of the ferritin receptors of human liver, hepatoma, lymphoid and erythroid cells. Journal of Inorganic Biochemistry, 1992, 47, 219-227.	1.5	64

#	Article	IF	Citations
199	Surival and prognostic factors in 212 Italian patients with genetic hemochromatosis. Hepatology, 1992, 15, 655-659.	3.6	208
200	Saturability of hepatic iron deposits in genetic hemochromatosis. Hepatology, 1992, 16, 956-959.	3.6	22
201	Hepatitis C virus and porphyria cutanea tarda: Evidence of a strong association. Hepatology, 1992, 16, 1322-1326.	3.6	298
202	Binding and suppressive activity of human recombinant ferritins on erythroid cells. American Journal of Hematology, 1992, 39, 264-268.	2.0	15
203	Characteristics of the Membrane Receptor for Human H-Ferritin. Current Studies in Hematology and Blood Transfusion, 1991, 58, 164-170.	0.2	11
204	Immunohistochemical evidence for a lack of ferritin in duodenal absorptive epithelial cells in idiopathic hemochromatosis. Gastroenterology, 1989, 96, 1071-1078.	0.6	72
205	Rare Atg7 Genetic Variants Predispose to Severe Fatty Liver Disease. SSRN Electronic Journal, 0, , .	0.4	0
206	Cardiovascular involvement after liver transplantation: role of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Exploration of Medicine, 0, , .	1.5	0